Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL21P87 is a processed pseudogene derived from the ribosomal protein L21 gene (RPL21)[7]. Pseudogenes are segments of DNA that resemble genes but are typically nonfunctional: they do not encode proteins nor RNA products that are biologically active. The RPL21P87 locus is cataloged in genomic databases such as HGNC (36411), NCBI Gene (100131672), and Ensembl (ENSG00000228053); however, there is no evidence it has any biological function, disease association, or utility as a drug target. The functional parent gene, ribosomal protein L21 (RPL21), is a component of the large 60S ribosomal subunit and is involved in protein synthesis, but this information does not apply to its pseudogene copies[1][3][7]. No interacting drugs, mechanisms of action, biomarker roles, or safety concerns have been documented for RPL21P87.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L21 pseudogene 87 (RPL21P87).